Pulmonary Hypertension Trials Network
Who We Are
The Pulmonary Hypertension Trials Network (PHTNet) coordinates and supports clinical trials in pulmonary hypertension across Australia and New Zealand. Our purpose is to strengthen trial delivery, accelerate research, and improve outcomes for people living with pulmonary hypertension.
PHTNet is a central point of contact for patients, carers, clinicians, researchers, and industry partners to access information about pulmonary hypertension clinical trials and connect with participating sites across Australasia.
We believe clinical research is essential to advancing care and delivering meaningful benefits for people with pulmonary hypertension.
Our Vision
To be a leading Australasian pulmonary hypertension clinical trials network, delivering high-quality research that leads to safe, effective, and accessible therapies.
Our Mission
To facilitate and coordinate high-quality pulmonary hypertension clinical trials across Australasia, strengthening local capacity and improving quality of life and survival for people living with pulmonary hypertension.
Our Objectives
Expand the pulmonary hypertension clinical trials portfolio across Australia and New Zealand
Improve awareness of and access to pulmonary hypertension clinical research for patients and clinicians
Support equitable trial access, including for regional and non-metropolitan patients
Strengthen national and international collaborations in pulmonary hypertension trials
Build early-phase trial capability and upskill the clinical trials workforce
Develop innovative approaches to accelerate trial timelines and expand the research pipeline
Why Participate in a Pulmonary Hypertension Clinical Trial?
Clinical trials play a vital role in improving care for people living with pulmonary hypertension (PH). Every approved PH treatment available today exists because patients chose to take part in clinical research.
What Are Clinical Trials?
Clinical trials carefully test new treatments, new combinations of treatments, or new ways of using existing therapies. They are conducted under strict ethical and safety standards and are closely monitored by specialist pulmonary hypertension teams.
Why Consider Taking Part?
Participation in a clinical trial may offer:
-
Access to new and emerging treatments
-
Close monitoring by specialist PH clinicians
-
The opportunity to contribute to future advances in PH care
While benefit cannot be guaranteed, many patients value the additional support and follow-up involved.
Your Safety and Choice
-
Participation is always voluntary
-
You can withdraw at any time without affecting your usual care
-
All trials are reviewed and approved by independent ethics committees
-
Your treating team remains involved throughout
Learn More
If you are living with pulmonary hypertension and would like to learn more about clinical trials, speak with your PH specialist or contact PHTNet to explore available studies across Australia and New Zealand.
Group 1 Pulmonary Arterial Hypertension
Group 2 PH due to Left Heart Disease
Group 3 PH due to lung disease
Group 4 Chronic thromboembolic pulmonary hypertension
High-quality clinical trials have transformed the treatment of pulmonary hypertension, helping to prevent exposure to ineffective or harmful therapies while providing access to treatments proven to improve symptoms, quality of life, and survival. Progress cannot be made without clinical trials.
Participation in clinical trials is increasingly recognised as an important component of best practice PH care. We encourage all clinicians to support trial awareness and refer patients who may benefit from participation.
For researchers, PHTNet offers access to a coordinated network of experienced pulmonary hypertension centres across Australia and New Zealand, supporting efficient, high-quality clinical trial delivery. Through PHTNet, investigators can accelerate feasibility, site engagement, and recruitment while maintaining academic leadership and fostering collaborative, innovative pulmonary hypertension research.
Australia and New Zealand offer a highly competitive environment for pulmonary hypertension (PH) clinical trials, supported by world-class clinical research infrastructure, streamlined regulatory pathways, and strong government incentives.
We offer:
- A collaborative network of experienced, internationally recognised PH investigators
- A proven track record of high-quality recruitment and retention in global pulmonary hypertension clinical trials
- A mature and integrated research ecosystem spanning academic centres, specialist hospitals, and clinical trial units
- Efficient multi-site ethics approval processes through national HREC frameworks and independent ethics providers
- The Clinical Trial Notification (CTN) scheme, enabling streamlined early-phase drug development